Novartis Provides Update on Delpacibart Etedesiran (del-desiran) Phase III HARBOR Study for the Treatment of Myotonic Dystrophy Type 1 (DM1)
Phase 3negativeDelpacibart EtedesiranNegative
AI Analysis
Summary
Novartis announced that its Phase III HARBOR study of del-desiran for myotonic dystrophy type 1 failed to meet its primary endpoint, showing no statistically significant improvement over placebo.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Not Met
Outcome Details
Phase III HARBOR study did not demonstrate statistically significant improvement versus placebo on primary endpoint
Importance:8/10
Sentiment:
-0.85
Phase 3 failuremyotonic dystrophyrare diseasenegative trial data
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 8, 2026 7:09 PM